PT  - JOURNAL ARTICLE
AU  - Ruigrok, Ynte M.
AU  - Veldink, Jan H.
AU  - Bakker, Mark K.
TI  - Drug classes affecting intracranial aneurysm risk: genetic correlation and Mendelian randomization
AID  - 10.1101/2023.10.23.23297443
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.10.23.23297443
4099  - http://medrxiv.org/content/early/2023/10/25/2023.10.23.23297443.short
4100  - http://medrxiv.org/content/early/2023/10/25/2023.10.23.23297443.full
AB  - Background There is no non-invasive treatment option to prevent aneurysmal subarachnoid hemorrhage (ASAH) caused by intracranial aneurysm (IA) rupture. We aimed to identify drug classes that may affect liability to IA using a genetic approach.Methods We obtained genome-wide association summary statistics for unruptured IA (N=2,140 cases), ASAH (N=5,140 cases), and the combined group (N=7,495 cases; N=71,934 controls in all groups), and drug usage from 23 drug classes (N up to 320,000) based on European-ancestry cohorts. We calculated genetic correlation between IA and ASAH, and liability to drug usage independent of the risk factor high blood pressure. Next, we evaluated the causality and therapeutic potential of independent correlated drug classes using three different Mendelian randomization frameworks.Results Blood pressure-independent correlations with IA were found for antidepressants, paracetamol, acetylsalicylic acid, opioids, beta-blockers, and peptic ulcer and gastro-oesophageal reflux disease drugs. MR showed that the genetically predicted usage of none of these drug classes were causally related to IA. Genetically predicted high responders to antidepressant drugs were at higher risk of IA (odds ratio [OR]=1.61, 95% confidence interval (CI)=1.09-2.39, P=0.018) and ASAH (OR=1.68, 95%CI=1.07-2.65, P=0.024) if they used antidepressant drugs. This effect was absent in non-users. For beta-blockers, additional analyses showed that this effect was not independent of blood pressure after all. Genetic liability to chronic multisite pain, an indication for pain medication (paracetamol, acetylsalicylic acid, and opioids), was associated with increased IA risk (OR=1.63, 95%CI=1.24-2.14), but not consistently across sensitivity analyses.Conclusions We did not find drugs decreasing liability to IA and ASAH but did find that antidepressant drugs may increase liability. In addition, we observed pleiotropy between IA, chronic pain, and pain medication usage, but the driving factor for this pleiotropy remains to be determined. Our results help to better understanding pathogenic mechanisms underlying IA.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was funded by the Collaboration for New Treatments of Acute Stroke (CONTRAST) consortium (https://contrast-consortium.nl). This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No. 852173).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Only publicly available aggregated data was used with informed consent in place in the original studies.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesOnly publicly available aggregated data was used with informed consent in place in the original studies. Data generated in this study is available in the Supplement.ASAHaneurysmal subarachnoid hemorrhageBPblood pressureCAUSECausal Analysis Using Summary Effect EstimatesCIconfidence intervalCMPChronic multisite painCNNM2Cyclin and CBS domain divalent metal cation transport mediator 2GSMRgeneralized summary statistics-based Mendelian randomizationGWASgenome-wide association studyIAintracranial aneurysmMRMendelian randomizationORodds ratioPGSpolygenetic scoreρggenetic correlationSSRIselective serotonin reuptake inhibitor